Medpace Stock Forecast, Price & News

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MEDP shares have increased by 71.4% and is now trading at $143.36.
View which stocks have been most impacted by COVID-19.

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Medpace stock.
View analyst ratings for Medpace or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Medpace a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medpace wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Medpace is scheduled to release its next quarterly earnings announcement on Monday, February 15th 2021.
View our earnings forecast for Medpace.

Medpace will be holding an earnings conference call on Monday, February 15th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Medpace Holdings, Inc. (NASDAQ:MEDP) released its quarterly earnings data on Saturday, October, 31st. The company reported $1.09 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.07 by $0.02. The firm had revenue of $230.37 million for the quarter, compared to analyst estimates of $223.56 million. Medpace had a return on equity of 17.67% and a net margin of 13.87%. Medpace's revenue for the quarter was up 6.5% compared to the same quarter last year. During the same period last year, the company posted $0.71 EPS.
View Medpace's earnings history.

Medpace updated its FY20 earnings guidance on Monday, October, 26th. The company provided EPS guidance of $3.62-3.83 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.95. The company issued revenue guidance of $880-920 million, compared to the consensus revenue estimate of $903.50 million.

6 Wall Street analysts have issued 12 month target prices for Medpace's stock. Their forecasts range from $75.00 to $135.00. On average, they expect Medpace's stock price to reach $103.00 in the next year. This suggests that the stock has a possible downside of 28.2%.
View analysts' price targets for Medpace or view Wall Street analyst' top-rated stocks.

Medpace saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 996,700 shares, an increase of 32.1% from the December 15th total of 754,400 shares. Based on an average daily volume of 248,700 shares, the days-to-cover ratio is currently 4.0 days. Approximately 3.6% of the shares of the stock are short sold.
View Medpace's Short Interest.

Some companies that are related to Medpace include Charles River Laboratories International (CRL), PPD (PPD), ICON Public (ICLR), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Precigen (PGEN), National Research (NRC), Starpharma (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Auxly Cannabis Group (CBWTF), Bioanalytical Systems (BASI) and Eloxx Pharmaceuticals (ELOX).
View all of MEDP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by a variety of retail and institutional investors. Top institutional investors include Boston Trust Walden Corp (1.42%), Tributary Capital Management LLC (0.49%), Scout Investments Inc. (0.29%), McGuire Investment Group LLC (0.14%), Exchange Traded Concepts LLC (0.03%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald and Susan E Burwig.
View institutional ownership trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, and State of Alaska Department of Revenue. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace or view top insider-selling stocks.

MEDP stock was bought by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Exchange Traded Concepts LLC, Mountain Capital Investment Advisors Inc, McGuire Investment Group LLC, Scout Investments Inc., Crossmark Global Holdings Inc., Louisiana State Employees Retirement System, and Sheets Smith Wealth Management.
View insider buying and selling activity for Medpace or or view top insider-buying stocks.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $143.36.

Medpace has a market capitalization of $5.13 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe.

The official website for Medpace is www.medpace.com.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]